156053-89-3

Product Details:

CasNo： 156053-89-3

Molecular Formula： C25H32N2O4

Appearance： White solid

Delivery Time： 2 weeks after order

Throughput： 100KG/Month

Purity： 99%

Synonyms: 2-([(2S)-2-([(3R,4R)-4-(3-Hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl)-3-phenylpropanoyl]amino)acetic acid; N-[(2S)-2-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-diMethyl-1-piperidinyl]Methyl]-1-oxo-3-phenylpropyl]glycine; 2-((S)-2-benzyl-3-((3R,4R)-4-(3-hydroxyphenyl)-3,4-diMethylpiperidin-1-yl)propanaMido)acetic acid; AlviMopan (ADL 8-2698); Alvimopan anhydrous; Glycine, N-((2S)-2-(((3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-1-oxo-3-phenylpropyl)-
Boiling point: 684.1±55.0 °C
Density: 1.166±0.06 g/cm3
Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated, Heated)
Pka: 3.39±0.10
Flash point: 367.5±31.5 °C
Vapor pressure: 0.0±2.2 mmHg at 25°C
Refractive index: 1.572

Description:
Alvimopan has its chemical name being 2-[[(2S)-2-[[(3R, 4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-piperidin-1-yl] methyl]-3-phenyl-propionyl] amino] acetic acid dihydrate.  It is a highly selective peripheral opioid antagonist which was jointly developed by the British company GlaxoSmithKline (GSK) and the United States Adolor company.  In May 2008, it was approved by the US FDA for entering into market for applying to promote the recovering of the gastrointestinal function of patients who have been subject to colon or small intestine stage I resection anastomosis.  Since the product can selectively inhibit the gastrointestinal opioid receptors without reducing the central analgesic effect of opioid agonists, therefore it does not affect the analgesic effect of systemic administration with safety and well-tolerance.

Biological Activity:
Alvimopan is a gastroprokinetic peripheral mu-opioid receptor antagonist. As a drug, Alvimopan is given to patients undergoing bowel surgery to protect the bowel from the effects of opioid medications th at are used to tre at pain, blocking the undesirable GI side-effects of the opioid agonists without affecting analgesia or causing withdrawal. Alvimopan does not cross the blood-brain barrier, competitively binding to gastrointestinal tract mu-opioid receptors.

Uses:
A peripheral μ-opioid receptor antagonist. Gastroprokinetic.
Flavenoid cytoprotective agent for the treatment of mucosal lesions.